However, while effective in controlling tumor growth with continuous dosing in the majority of patients, MEK inhibitors do not offer a cure and are associated with notable adverse effects, including papulopustular rash, xerosis, and pruritus (Figure 2) [67]. Here, MAP2K7 is linked to neoplasm.